Table 3. Postimplementation program evaluation data for 2 Lighthouse Trust pilot sites in Lilongwe, Malawi, February 2015 to June 2016.
| Characteristic | Total |
|---|---|
| Screening parameters | |
| Number of persons screened*† | 29,359 |
| Median age (IQR) | 38 (32–45) |
| Male gender (%) | 11,794 (39) |
| Diagnosis parameters | |
| Number newly diagnosed with hypertension (%)‡ | 3,448 (11) |
| Mild (SBP 140–159 or DBP 90–99) | 1,619 (47) |
| Moderate (SBP 160–179 or DBP 100–109) | 514 (15) |
| Severe (SBP ≥ 180 or DBP ≥ 110) | 1,315 (38) |
| Treatment parameters | |
| Number of hypertensive patients started on treatment or given lifestyle advice (%) | 2,915 (85) |
| Number of all hypertensive patients on pharmacologic treatment for hypertension (%)ǁ | 1,681 (49) |
| Control parameters | |
| Of those on treatment for 3 months, number with normal blood pressure at last visit (%) | 240 (22) |
| Of those on treatment for 6 months, number with normal blood pressure at last visit (%) | 229 (26) |
| Adherence parameters | |
| Number of hypertensive patients on treatment with at least 95% antiretroviral adherence | 1,165 (80) |
| Number of patient without hypertension with at least 95% antiretroviral adherence | 20,073 (79) |
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
*A phased approach was used at the Martin Preuss Clinic; therefore, the program was considered fully operational in June 2015, and the evaluation period extended to 12 months from this date to June 2016.
†All patients were screened with an automated sphygmomanometer.
‡The definition of a new diagnosis of hypertension (HTN) was based on Malawi Standard Treatment Guidelines (fourth edition): SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg measured on 2 consecutive visits or severe HTN (SBP ≥ 180 mm Hg or DBP ≥ 110 mm Hg) on a single visit.
ǁProvision for treatment: all persons with moderate or severe HTN were eligible for treatment. For those with mild HTN, only lifestyle modifications were suggested unless the individual had one cardiovascular disease (CVD) risk factor (current smoker, diabetes mellitus [DM], history of CVD, or history of CVD in a first-degree relative).